- Home
- LVLU vs ATNM Comparison
LVLU vs ATNM Comparison
Compare LVLU & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LVLU | ATNM |
|---|---|---|
| Founded | 1996 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.6M | 31.7M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | LVLU | ATNM |
|---|---|---|
| Price | $7.29 | $1.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 5.9K | ★ 120.9K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.17 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $282,284,000.00 | $90,000.00 |
| Revenue This Year | $5.66 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $0.22 | $0.95 |
| 52 Week High | $32.32 | $1.89 |
Technical Indicators
Market Signals| Indicator | LVLU | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 29.40 | 42.34 |
| Support Level | $7.23 | $0.99 |
| Resistance Level | $11.21 | $1.27 |
| Average True Range (ATR) | 0.91 | 0.07 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 2.25 | 19.35 |
Price Performance
Historical ComparisonAbout LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.